Please Wait...

OC // Osteocalcin

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

Osteocalcin (OC), also called bone γ-carboxyglutamic acid protein (BGP), is a 49 residues containing non-collagenous protein found in bone and dental tissues. OC is produced by osteoblasts and is a vitamin K dependent protein implicated in bone formation. Initially identified as a protein limiting bone formation, new functions such as implication in glucose metabolism, reproduction and cognition have been identified since (Ducy et al., 1996; Zoch et al., 2016). OC binds to hydroxyapatite and a fraction of the newly synthetized protein is then released in blood circulation. The binding to hydroxyapatite is impaired when OC is decarboxylated (Price et al., 1981). In addition to this source of variation in biological activities, intact OC is rapidly cleaved by proteolytic enzymes and is unstable in vitro. In serum, several proteolytic fragments of OC are present and the N-terminal-mid fragment (N-Mid) is the most abundant immunoreactive form (about 30% of total OC)(Garnero et al., 1994).

Bioclinica Lab employs an automated electro-chemiluminescence immunoassay which recognizes the N-Mid OC. The assay for UcOC measurement is a twostep assay, which comprises an affinity depletion of carboxylated OC in samples with hydroxyapatite followed by an immunoassay for the measurement of the non-bound OC.

ADDITIONAL RESOURCES

Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

We're hiring recent tech grads in #RTP for #pharma sector! Our innov. clinical financial solution gives our client… https://t.co/GHgOfszO0T
bioclinica (3 hours ago)
Great to be @DrugInfoAssn DIA China! Ask us @bioclinica how sponsors & CROs can optimize electronic data capture… https://t.co/TtE4AiLnqY
bioclinica (9 hours ago)
RT @bioclinica: Kinks in the clinical supply chain? Check out how one of our clients is using clinical supply optimization technology for m…
bioclinica (9 hours ago)
RT @bioclinica: Welcoming everyone to KOP for #OCTEast Coast!!
bioclinica (9 hours ago)
Welcoming everyone to KOP for #OCTEast Coast!!
bioclinica (Yesterday)
Case processing is an important aspect of post-marketing drug safety surveillance. Here's a case study showing how… https://t.co/UMYp92Puvc
bioclinica (2 days ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen